Modi P, Suleiman M-S, Reeves B, Pawade A, Parry A J, Angelini G D, Caputo M
Bristol Heart Institute, University of Bristol, Bristol Royal Infirmary, Bristol, United Kingdom.
J Thorac Cardiovasc Surg. 2004 Jul;128(1):67-75. doi: 10.1016/j.jtcvs.2003.11.071.
Blood cardioplegia and terminal warm blood cardioplegic reperfusion ("hot shot") reduce myocardial injury and improve metabolic recovery in hypoxic but not normoxic experimental models. However, there is little evidence of a benefit of either technique in pediatric clinical practice compared with crystalloid cardioplegia.
Pediatric patients undergoing cardiac surgery were randomized to receive intermittent antegrade cold crystalloid cardioplegia, cold blood cardioplegia, or cold blood cardioplegia with a hot shot. Right ventricular biopsy specimens were collected before ischemia, at the end of ischemia, and 20 minutes after reperfusion. Cellular metabolites were analyzed. In acyanotic patients postoperative serum troponin I levels were also measured at 1, 4, 12, 24, and 48 hours.
Of 103 patients recruited, 32 (22 acyanotic and 10 cyanotic), 36 (24 acyanotic and 12 cyanotic), and 35 (25 acyanotic and 10 cyanotic), respectively, were allocated to the groups receiving cold crystalloid cardioplegia, cold blood cardioplegia, and cold blood cardioplegia with a hot shot. Cyanotic patients were younger, with longer crossclamp times. There were no significant differences in clinical outcomes between cardioplegic methods. The cardioplegic method had no overall effect in terms of adenosine triphosphate, ln(adenosine triphosphate/adenosine diphosphate), or ln(glutamate) in acyanotic patients (P =.11, P =.66, and P =.30, respectively). Also, there was no significant difference between groups in troponin I release. However, in cyanotic patients cold blood cardioplegia with a hot shot significantly reduced the decrease in adenosine triphosphate, ln(adenosine triphosphate/adenosine diphosphate), and glutamate observed at the end of ischemia and after reperfusion compared with the decrease seen in those receiving cold crystalloid cardioplegia (P =.002, P =.003, and P =.008, respectively), with cold blood cardioplegia representing an intermediate.
For cyanotic patients (younger, with longer crossclamp times), cold blood cardioplegia with a hot shot is the best method of myocardial protection. For acyanotic patients (older, with shorter crossclamp times), cardioplegic technique is not critical.
在缺氧而非正常氧合的实验模型中,血液停搏液和终末温血心脏停搏液再灌注(“热灌注”)可减少心肌损伤并改善代谢恢复。然而,与晶体停搏液相比,在儿科临床实践中几乎没有证据表明这两种技术有任何益处。
接受心脏手术的儿科患者被随机分为接受间歇性顺行冷晶体停搏液、冷血停搏液或冷血停搏液加“热灌注”。在缺血前、缺血结束时和再灌注后20分钟采集右心室活检标本。分析细胞代谢物。对于非紫绀型患者,还在术后1、4、12、24和48小时测量血清肌钙蛋白I水平。
在招募的103例患者中,分别有32例(22例非紫绀型和10例紫绀型)、36例(24例非紫绀型和12例紫绀型)和35例(25例非紫绀型和10例紫绀型)被分配到接受冷晶体停搏液、冷血停搏液和冷血停搏液加“热灌注”的组中。紫绀型患者年龄较小,体外循环阻断时间较长。停搏液方法之间的临床结果无显著差异。停搏液方法对非紫绀型患者的三磷酸腺苷、ln(三磷酸腺苷/二磷酸腺苷)或ln(谷氨酸)没有总体影响(分别为P = 0.11、P = 0.66和P = 0.30)。此外,各组之间肌钙蛋白I释放无显著差异。然而,在紫绀型患者中,与接受冷晶体停搏液的患者相比,冷血停搏液加“热灌注”显著减少了缺血结束时和再灌注后观察到的三磷酸腺苷、ln(三磷酸腺苷/二磷酸腺苷)和谷氨酸的下降(分别为P = 0.002、P = 0.003和P = 0.008),冷血停搏液则介于两者之间。
对于紫绀型患者(年龄较小,体外循环阻断时间较长),冷血停搏液加“热灌注”是心肌保护的最佳方法。对于非紫绀型患者(年龄较大,体外循环阻断时间较短),停搏液技术并不关键。